Head-to-head · free
Baxter International Inc. vs BioStem Technologies, Inc.
BAX vs BSEM — return on capital, cash generation, margins and balance sheet side by side.
BAX
0 / 0
measures where BAX leads
BSEM
0 / 0
measures where BSEM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | BAX · FY2025 | BSEM |
|---|---|---|
| Revenue | $11.2B | — |
| Net income | (957.0M) | — |
| Revenue growth (yearly, multi-year) | -3.2% | — |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -14.6% | — |
| Gross margin | 30.1% | — |
| Operating margin | 1.6% | — |
| Net debt / EBITDA | 11.16x | — |
Figures are as reported by each company; latest fiscal year shown.
Where Baxter International Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free